US 12,186,323 B2
Combination drugs of hypoxanthine and human immunoglobulin
Zongkui Wang, Sichuan (CN); Ming Cui, Tianjin (CN); Changqing Li, Sichuan (CN); Jun Xu, Shanghai (CN); and Lu Cheng, Shanghai (CN)
Assigned to Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Sichuan (CN); Institute of Radiation Medicine, Chinese Academy of Medical Sciences, Tianjin (CN); and Shanghai RAAS Blood Products Co., Ltd., Shanghai (CN)
Filed by Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Sichuan (CN); Institute of Radiation Medicine, Chinese Academy of Medical Sciences, Tianjin (CN); and Shanghai RAAS Blood Products Co., Ltd., Shanghai (CN)
Filed on Jul. 11, 2022, as Appl. No. 17/811,715.
Claims priority of application No. 202110791985.4 (CN), filed on Jul. 13, 2021.
Prior Publication US 2022/0339158 A1, Oct. 27, 2022
Int. Cl. A61K 31/522 (2006.01); A61K 9/00 (2006.01); A61K 39/395 (2006.01); A61P 43/00 (2006.01)
CPC A61K 31/522 (2013.01) [A61K 9/0019 (2013.01); A61K 39/395 (2013.01); A61P 43/00 (2018.01)] 9 Claims
OG exemplary drawing
 
1. A combination drug for the treatment of radiation injuries for a subject in need thereof, comprising hypoxanthine and human immunoglobulin (HIg), wherein:
said HIg is selected from intravenous immunoglobulin (IVIg), intramuscular immunoglobulin (IMIg), subcutaneous immunoglobulin (SCIg), and mixtures thereof; and
the mass of hypoxanthine is 50 mg/kg calculated based on the subject's weight; and
the mass ratio of hypoxanthine to HIg is from 1:1 to 1:11.